Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE

Endo Buying Par Pharma In Generics Push

By Pharmaceutical Processing | May 18, 2015

In this Nov. 3, 2011 file photo, Sanj Patel, President and CEO of Synageva BioPharma Corp., attends the opening bell ceremony at Nasdaq in New York. Alexion Pharmaceuticals on Wednesday, May 6, 2015 announced it is spending $8.4 billion to buy fellow rare disease treatment maker Synageva BioPharma, a company with no products on the market. (AP Photo/Mark Lennihan, File)NEW YORK (AP) — Endo International will spend about $8.05 billion to acquire Par Pharmaceutical as it pushes further into the generic drug market.

Endo CEO Rajiv De Silva said the deal make Endo one of the top five generics companies as measured by U.S. sales.

Endo, based in Dublin, said it expects its generic drug unit to see double-digit revenue growth with the addition of Par.

Par, based in Chestnut Ridge, New York, was acquired by the private equity firm TPG in 2012. The deal is expected to close in the second half of 2015.

The buyout follows Endo’s failed attempt to buy Salix Pharmaceutical Ltd. after being outbid by Valeant Pharmaceutical. In March, Valeant raised its offer to about $11.11 billion, forcing Endo out of the running.

“This transaction with Par builds upon our generics growth, adding a strong portfolio of high barrier-to-entry and attractive gross margin products,” Endo CEO Rajiv De Silva said in a printed statement.

The deal includes about 18 million shares of Endo stock and $6.5 billion in cash, along with the assumption of debt.

Endo’s branded products include the pain treatment Opana ER and the numbing agent Lidoderm. That unit had $285 million in revenue during the company’s first quarter. The generics unit had $357 million in sales during that period.

Shares of Endo International Plc. rose $1.93, or 2.2 percent, to $87.30 in premarket trading.

Related Articles Read More >

Bayer plans to build $2.2B Ohio drug manufacturing site
GSK
GSK invests another $800M in Pennsylvania site expansions
This is a BD image of its major IV catheters manufacturing facility in Sandy, Utah, which the company said produces billions of molded components each year.
BD to invest billions in U.S. manufacturing
These are the logos of GE HealthCare and Sofie Biosciences.
GE HealthCare to buy Sofie Biosciences in $945M radiopharmaceutical play
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2026 Arrowfly LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Resources
    • Voices
  • Advertisers
    • Advertise
    • PR Submissions
    • Eblast Submissions
  • SUBSCRIBE